Imclone have just announced their 1st Qtr 2004 earnings . Revenues have rocketed to 109.6 million USD with a net of 62.7 million USD . All this on the sales of their new drug for metastatic colorectal cancer ,erbitux . This is a marginal drug at best , with response time in combination with chemo of 5.7 months before disease progression and 1.5 months as a stand alone treatment .
That looks ordinary compared to what Solbec were seeing in their special access patients .
SBP
solbec pharmaceuticals limited
Imclone have just announced their 1st Qtr 2004 earnings ....
Add to My Watchlist
What is My Watchlist?